2026-05-17T00:18:20Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/170662024-11-28T15:14:20Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Hernández, Domingo author Ruiz-Esteban, Pedro author Gaitán, Daniel author Burgos, Dolores author Mazuecos, Auxiliadora author Collantes, Rocío author Briceño, Eva author Palma, Eulalia author Cabello, Mercedes author González-Molina, Miguel author De Mora, Manuel author 2014-04-23 BACKGROUND: Left ventricular hypertrophy (LVH) is common in kidney transplant (KT) recipients. LVH is associated with a worse outcome, though m-TOR therapy may help to revert this complication. We therefore conducted a longitudinal study to assess morphological and functional echocardiographic changes after conversion from CNI to m-TOR inhibitor drugs in nondiabetic KT patients who had previously received RAS blockers during the follow-up. METHODS: We undertook a 1-year nonrandomized controlled study in 30 non-diabetic KT patients who were converted from calcineurin inhibitor (CNI) to m-TOR therapy. A control group received immunosuppressive therapy based on CNIs. Two echocardiograms were done during the follow-up. RESULTS: Nineteen patients were switched to SRL and 11 to EVL. The m-TOR group showed a significant reduction in LVMi after 1 year (from 62 ± 22 to 55 ± 20 g/m2.7; P=0.003, paired t-test). A higher proportion of patients showing LVMi reduction was observed in the m-TOR group (53.3 versus 29.3%, P=0.048) at the study end. In addition, only 56% of the m-TOR patients had LVH at the study end compared to 77% of the control group (P=0.047). A significant change from baseline in deceleration time in early diastole was observed in the m-TOR group compared with the control group (P=0.019). CONCLUSIONS: Switching from CNI to m-TOR therapy in non-diabetic KT patients may regress LVH, independently of blood pressure changes and follow-up time. This suggests a direct non-hemodynamic effect of m-TOR drugs on cardiac mass. 10.1186/1471-2369-15-65 1471-2369 BMC Nephrology http://hdl.handle.net/10668/2043 24755192 http://hdl.handle.net/20.500.12105/17066 Everolimus Left ventricular hupertrophy Renin-angiotensis blockers Sirolimus Kidney transplantation Inhibidores de la enzima convertidora de angiotensina Farmacoterapia combinada Hipertrofia ventricular izquierda Inmunosupresores Trasplante de riñón Inhibidores de proteínas cinasas TOR serina-treonina cinasas Resultado del tratamiento Antagonistas de receptores de angiotensina Regression of cardiac growth in kidney transplant recipients using anti-m-TOR drugs plus RAS blockers: a controlled longitudinal study.